Public company, workplace, funding, and market signals
Updated Aug 16, 2026
DELFI Diagnostics is a privately held cancer-diagnostics company developing blood-based tests that use AI, machine learning, whole-genome sequencing, and cell-free DNA fragmentomics to improve cancer detection and treatment monitoring. Its stated mission is to make early cancer detection more accessible, including for underserved populations.
Primary product
FirstLook Lung™: a laboratory-developed blood test intended to help identify individuals at elevated risk of lung cancer and guide follow-up with guideline-recommended low-dose CT. DELFI also offers DELFI-TF, a research-use-only tumor-fraction assay for treatment monitoring.
Founded
2019
Headquarters
1810 Embarcadero Road, Palo Alto, California 94303, United States
Team size
51-200
Industry
Medical and Diagnostic Laboratories
Sub-industry
Liquid biopsy, cancer diagnostics, clinical laboratory testing, and precision oncology
Offices
Business model
Stage
Late-stage private / commercializing diagnostics company
Total raised
$364.8M
Latest round
Rule 506(b) private financing · Dec 2025
Latest amount
$34.3M
Dec 2025
Strategic equity investment / venture round
Jun 2024 · Merck Global Health Innovation Fund
Jul 2022
Jan 2021 · OrbiMed
Aug 2019 · Menlo Ventures
Jan 2019
Leadership
Chief Executive Officer
Founder and Board Member; former CEO
Co-Founder and Head of Data Science / Senior Strategy Advisor
Chief Medical Officer
Amoolya Singh
Chief Technology Officer
Chief Financial Officer
Vice President, Medical Affairs
Head of Translational Science
Senior Medical Director
Ally Dashner
Chief People Officer
Lee-Ann Smith-Freeman
Vice President of Legal / General Counsel
Board Member
Public company materials emphasize scientific rigor, accessibility, health equity, cross-functional collaboration, and translating academic research into scalable clinical products. The company has publicly highlighted underserved populations and partnerships with health systems. A third-party employer-data profile reports an overall rating of approximately 4.2/5 from 27 reviews, with culture rated approximately 4.6/5; this is directional rather than an official company statement.
Compensation
Public compensation data is limited. No reliable DELFI-specific salary bands or equity terms were identified. Third-party employer data reports compensation satisfaction of approximately 4.3/5, but this should not be treated as verified compensation benchmarking.
Pricing
Not publicly disclosed. FirstLook Lung is offered through health-system and laboratory channels; the company is pursuing reimbursement and has not published a standard self-pay price in the reviewed sources.
Differentiators
Technology
Customers
Competitors
Estimated revenue
Approximately $1M-$10M annually; one third-party company profile estimates $7.6M
Estimated monthly visits
4.8K
Traffic estimate as of Jun 2026
FirstLook Lung remains a laboratory-developed test and has not been cleared or approved by the FDA. DELFI received New York State authorization to offer the test, but FDA in-vitro diagnostic approval remains a separate and material regulatory milestone.
SourceThe company is seeking broader payer reimbursement and expects future clinical, guideline, and regulatory milestones to be important to commercial adoption. Pricing and reimbursement terms remain largely undisclosed.
SourceThird-party employee data indicates approximately 98 employees and a year-over-year decline of about 10.7%. This is a workforce trend signal, not evidence of a confirmed layoff event.
SourceDELFI Diagnostics / PR Newswire · May 2026
DELFI announced New York State authorization for FirstLook Lung, making the laboratory-developed test available in all 50 states while it continues pursuing FDA approval.
GenomeWeb · May 2026
GenomeWeb reported FIRSTLUNG results showing approximately 80% sensitivity, 56% specificity, and a 99.8% negative predictive value; access to the assay increased overall screening roughly threefold and low-dose CT screening approximately 1.5-fold.
DELFI Diagnostics / PR Newswire · May 2026
The company announced five ATS 2026 presentations covering clinical utility, real-world implementation, health equity, and at-home blood collection for lung cancer screening.
DELFI Diagnostics / PR Newswire · Jan 2026
Cindy Soriano was promoted to CFO after serving as VP of Finance and Investor Relations; the company highlighted upcoming clinical and regulatory milestones.
DELFI Diagnostics / PR Newswire · Jun 2024
Merck's corporate venture arm made an undisclosed equity investment to accelerate DELFI's AI-enabled fragmentomics platform and cancer-detection commercialization.
9 jobs at Delfi Diagnostics